Q-omics provides the consensus-scored CLHC1 profile across patient tissues and cancer cell-line models. CLHC1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, CLHC1 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, CLHC1 RNA expression shows 20,667 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BLCA, COAD, and ACC as cancer lineages where CLHC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLHC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLHC1 survival associations across molecular data types. CLHC1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLHC1 RNA expression–survival associations across cancer types. High CLHC1 expression shows unfavorable associations in COAD, ACC, LIHC, KIRC and CHOL, but favorable associations in BLCA. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for CLHC1 RNA expression.
This table summarizes CLHC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for CLHC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLHC1 shows lower tumor expression in KICH, THCA and KIRC and higher tumor expression in COAD, LIHC and CHOL. The COAD box plot shows higher CLHC1 RNA expression in tumor versus normal tissue (log2 FC = +0.458, t-test p < 0.001).
This table shows molecular features associated with CLHC1 in patient tissues and cancer cell lines. In patient samples, CLHC1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CLHC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
